[{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"51e03560-3fbd-46cb-a1fe-077e9eea8d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT05681039","created_at":"2023-01-11T14:59:21.452Z","updated_at":"2025-02-25T15:44:59.452Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).","source_id_and_acronym":"NCT05681039","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-10"},{"id":"696d727b-575b-4b42-9ab7-71058751cfe0","acronym":"NCI-2021-13902","url":"https://clinicaltrials.gov/study/NCT05172258","created_at":"2021-12-29T13:53:34.637Z","updated_at":"2025-02-25T16:32:39.281Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","source_id_and_acronym":"NCT05172258 - NCI-2021-13902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"b69ba720-deab-42dc-9517-e6067c868218","acronym":"OSCC","url":"https://clinicaltrials.gov/study/NCT06728618","created_at":"2025-02-26T10:02:49.401Z","updated_at":"2025-02-26T10:02:49.401Z","phase":"Phase 2","brief_title":"Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06728618 - OSCC","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-12-11"},{"id":"e5c65e48-a957-4b92-b313-8ca9fc5212ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03435952","created_at":"2021-01-18T16:57:22.872Z","updated_at":"2025-02-25T16:07:34.095Z","phase":"Phase 1","brief_title":"Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT","source_id_and_acronym":"NCT03435952","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Clostridium novyi-NT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-10-31"},{"id":"117dd7b5-3dd5-44f8-ae41-dd01937e2c0d","acronym":"EGFR","url":"https://clinicaltrials.gov/study/NCT06606301","created_at":"2025-02-26T14:54:38.136Z","updated_at":"2025-02-26T14:54:38.136Z","phase":"","brief_title":"Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT06606301 - EGFR","lead_sponsor":"Combined Military Hospital, Pakistan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 08/26/2023","start_date":" 08/26/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/28/2023","study_completion_date":" 12/28/2023","last_update_posted":"2024-09-24"},{"id":"d34f9c68-d289-4614-b7bb-c24b096c0e1b","acronym":"KEYCHAIN","url":"https://clinicaltrials.gov/study/NCT03383094","created_at":"2025-02-25T16:07:22.270Z","updated_at":"2025-02-25T16:07:22.270Z","phase":"Phase 2","brief_title":"Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer","source_id_and_acronym":"NCT03383094 - KEYCHAIN","lead_sponsor":"Loren Mell, MD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-08-06"},{"id":"44c38d9e-4e4d-42d4-aeec-fdbf49756583","acronym":"","url":"https://clinicaltrials.gov/study/NCT03529422","created_at":"2021-01-18T17:22:35.201Z","updated_at":"2025-02-25T15:07:38.095Z","phase":"Phase 2","brief_title":"Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN","source_id_and_acronym":"NCT03529422","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/07/2019","start_date":" 10/07/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 05/06/2026","study_completion_date":" 05/06/2026","last_update_posted":"2024-07-16"},{"id":"d6e87e41-b021-47df-8cf1-eb7b999e061c","acronym":"DUTRELASCO","url":"https://clinicaltrials.gov/study/NCT03784066","created_at":"2021-01-18T18:42:49.153Z","updated_at":"2025-02-25T15:08:12.296Z","phase":"Phase 1/2","brief_title":"Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT03784066 - DUTRELASCO","lead_sponsor":"Universitaire Ziekenhuizen KU Leuven","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2026","study_completion_date":" 03/24/2026","last_update_posted":"2024-07-02"},{"id":"c99db0f5-d093-438e-9611-dd52b6a2e714","acronym":"","url":"https://clinicaltrials.gov/study/NCT06471270","created_at":"2025-02-26T14:18:15.906Z","updated_at":"2025-02-26T14:18:15.906Z","phase":"","brief_title":"Validation of Salivary Proteomic Biomarkers for Early Detection of Oral Cancer in Egyptian Population","source_id_and_acronym":"NCT06471270","lead_sponsor":"British University In Egypt","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/15/2024","study_completion_date":" 03/15/2024","last_update_posted":"2024-06-24"},{"id":"cd4d49d0-ea86-4fbe-8e14-261f63226683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06469892","created_at":"2025-02-26T14:17:49.764Z","updated_at":"2025-02-26T14:17:49.764Z","phase":"","brief_title":"Saliva and Plasma Exosomes for Oral Leukoplakia Malignant Transformation Diagnosis and Oral Cancer Prognosis Monitoring","source_id_and_acronym":"NCT06469892","lead_sponsor":"Beijing Stomatological Hospital, Capital Medical University","biomarkers":" miR-185","pipe":"","alterations":" ","tags":["miR-185"],"overall_status":"Completed","enrollment":" Enrollment 225","initiation":"Initiation: 06/13/2020","start_date":" 06/13/2020","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-06-24"},{"id":"80611a75-8e50-4af0-8595-0b4412326e20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576091","created_at":"2021-01-18T21:50:45.107Z","updated_at":"2024-07-02T16:34:37.303Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT04576091","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-06-07"},{"id":"939d1cf5-27ac-48f1-9f3d-96f6a19b535a","acronym":"NRG-HN008","url":"https://clinicaltrials.gov/study/NCT04533750","created_at":"2021-01-29T07:21:21.551Z","updated_at":"2024-07-02T16:34:37.751Z","phase":"Phase 1","brief_title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","source_id_and_acronym":"NCT04533750 - NRG-HN008","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"c8b861fe-9535-4dcc-814c-0f3b487628c9","acronym":"FX-909-CLINPRO-1","url":"https://clinicaltrials.gov/study/NCT05929235","created_at":"2023-07-03T16:10:43.192Z","updated_at":"2024-07-02T16:34:59.877Z","phase":"Phase 1","brief_title":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT05929235 - FX-909-CLINPRO-1","lead_sponsor":"Flare Therapeutics Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FX-909"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2024-05-31"},{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"d0153928-4f3a-4389-b410-c4dadfbfca07","acronym":"","url":"https://clinicaltrials.gov/study/NCT04754321","created_at":"2021-02-15T13:53:30.708Z","updated_at":"2024-07-02T16:35:02.445Z","phase":"Phase 1","brief_title":"Combining Immunotherapy Salvage Surgery \u0026 IORT Tx Persistent/Recurrent Head \u0026 Neck Cancer","source_id_and_acronym":"NCT04754321","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/12/2022","start_date":" 05/12/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-21"},{"id":"5d93f81b-6363-4cfb-8546-e62fcaccc6be","acronym":"NEOPBOSCC","url":"https://clinicaltrials.gov/study/NCT04649476","created_at":"2024-04-12T13:44:42.720Z","updated_at":"2024-07-02T16:35:09.900Z","phase":"Phase 2","brief_title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT04649476 - NEOPBOSCC","lead_sponsor":"Hospital of Stomatology, Wuhan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 03/22/2021","start_date":" 03/22/2021","primary_txt":" Primary completion: 08/10/2022","primary_completion_date":" 08/10/2022","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-04-12"},{"id":"8376cad8-b86a-4e59-8de8-f0511fd2d60b","acronym":"NEOPCOSCC","url":"https://clinicaltrials.gov/study/NCT05798793","created_at":"2024-02-05T15:19:44.475Z","updated_at":"2024-07-02T16:35:11.846Z","phase":"Phase 3","brief_title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT05798793 - NEOPCOSCC","lead_sponsor":"Hospital of Stomatology, Wuhan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 11/21/2023","start_date":" 11/21/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-02"},{"id":"a7a0ece0-f8fd-4b27-9854-748a124c975f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03342911","created_at":"2021-01-18T16:30:35.358Z","updated_at":"2025-02-25T14:37:41.222Z","phase":"Phase 2","brief_title":"Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT03342911","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 11/13/2017","start_date":" 11/13/2017","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-04-01"},{"id":"79fc19fa-8e81-4240-8411-e1af2a9cdd37","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084845","created_at":"2023-10-16T15:12:57.739Z","updated_at":"2024-07-02T16:35:14.380Z","phase":"Phase 2","brief_title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","source_id_and_acronym":"NCT06084845","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" TNFA","pipe":" | ","alterations":" CDKN2A negative","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • xevinapant (Debio 1143)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-03-15"},{"id":"c2798bea-d53d-468b-9a48-fa6038ef935d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03326947","created_at":"2022-05-26T23:55:05.469Z","updated_at":"2024-07-02T16:35:18.484Z","phase":"Phase 2","brief_title":"Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC","source_id_and_acronym":"NCT03326947","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" STMN1","pipe":"","alterations":" ","tags":["STMN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-20"},{"id":"b14136e7-6351-43ad-b0f1-c1c1e7064e34","acronym":"","url":"https://clinicaltrials.gov/study/NCT06154551","created_at":"2023-12-04T19:35:35.804Z","updated_at":"2024-07-02T16:35:27.274Z","phase":"","brief_title":"Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions","source_id_and_acronym":"NCT06154551","lead_sponsor":"Cairo University","biomarkers":" PXN","pipe":"","alterations":" ","tags":["PXN"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-12-04"}]